BeOne Medicines I GmbH
Budget
€25 — €0
EP Access
0
accredited persons
Staff
1
0.5 FTE
EU Grants
None
Mission & Goals
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team of nearly 12,000 colleagues spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
EU Legislative Interests
We follow EU policy developments, initiatives and legislative proposals relating to the innovative biotechnology industry for example the ongoing revision of the EU pharmaceutical legislation. We are also interested in EU health policy as it regards the therapy areas in which we operate, primarily cancer. - Clinical trials & regulatory modernisation - Biotech Act - Pricing & reimbursement - HTA Regulation - Value-based procurement and joint procurement - Critical Medicines Act - Oncology policy - Haematology policy - Revision of the general pharmaceutical legislation - MFF - Industrial Strategy - Trade agreements - Green Deal - Digital & AI Act - ESG & sustainability
Communication Activities
NA for 2025
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EUCOPE, EHA, ESMO, Oncosuisse, VFA, Leem, Pharma.be, Farmaindustria, Apifarma, Pharmig, VIPS, Hollandbio
Commissioner Meetings
No recorded meetings with EU commissioners.